A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: Expression, purification, and characterization

Cancer

Volumn 107, Issue 12, 2006, Pages 2760-2769

  Smirnoff, Patricia ^a   Roiz, Levava ^a   Angelkovitch, Boaz ^a   Schwartz, Betty ^a   Shoseyov, Oded ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Actin binding; Antiangiogenic; Colon cancer; Paclitaxel; RNASET2

Indexed keywords

1 [3 (DIMETHYLAMINO)PROPYL] 3 ETHYLCARBOIMIDE METHIODIDE; ACTIN; ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY DNA; CONCANAMYCIN A; G ACTIN; GLYCOPROTEIN; IMIDE; IMMUNOGLOBULIN M ANTIBODY; ISOPROPAMIDE IODIDE; MATING HORMONE ALPHA FACTOR; METHANOL; PACLITAXEL; PROPANE; RECOMBINANT HUMAN RNASET2 GLYCOPROTEIN; RIBONUCLEASE; SEPHAROSE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONOGENESIS; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; CROSS LINKING; DISEASE ASSOCIATION; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE DELETION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUDE MOUSE; PICHIA PASTORIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; SUPERNATANT; UMBILICAL VEIN; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CLONING, MOLECULAR; ENDOTHELIAL CELLS; GLYCOPROTEINS; HUMANS; MICE; MICE, NUDE; PACLITAXEL; PICHIA; RECOMBINANT PROTEINS; RIBONUCLEASES; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845568501     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22327     Document Type: Article

References (49)

1. Irie M, Ohgi K. Ribonuclease T2. Methods Enzymol. 2001;341:42-55.
2. Schein CH. From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Nature Biotech. 1997;15:529-536.
3. Deshpande RA, Shankar V. Ribonucleases from T2 family. Crit Rev Microbiol. 2002;28:79-122.
4. Roiz L, Ozeri U, Goren R, Shoseyov O. Characterization of Aspergillus niger B-1 RNase and its inhibitory effect on pollen germination and pollen tube growth in selected tree fruit. J Am Soc Hort Sci. 2000;125:9-14.
5. Janmey PA, Chaponnier C. Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol. 1995;7:111-117.
6. 2-RNaSe with antiangiogenic and anticarcinogenic characteristics. Cancer. 2006;106:2295-2308.
7. Cooke IE, Shelling AN, Le Meuth VG, Charnock ML, Ganesan TS. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosomes Cancer. 1996;15:223-233.
8. Saito S, Saito H, Ko S, et al. Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. Cancer Res. 1992;52:5815-5817.
9. Develee P, van Vliet M, van Sloun Kuipers N, Hermans J, Pearson P, Cornelisse C. Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene. 1991;6:1705-1711.
10. Theile M, Seitz S, Arnold W, et al. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene. 1996;13:677-685.
11. Tibiletti MG, Sessa F, Bernasconi B, et al. A large 6q deletion is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions, and carcinomas of the breast. Clin Cancer Res. 2000;6:1422-1431.
12. Chappell S, Walsh T, Walker R, Show J. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer. 1997;75:1324-1329.
13. Queimado L, Seruca R, Costa-Pereira A, Castedo S. Identification of two distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosomes Cancer. 1995;14:28-34.
14. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene. 1995;10:1725-1729.
15. Honchel R, McDonnell S, Schaid D, Thibodeau S. Tumor necrosis factor-alpha allelic frequency and chromosome 6 allelic imbalance in patients with colorectal cancer. Cancer Res. 1996;56:145-149.
16. Morita R, Saito S, Ishikawa J, et al. Common region of deletion on chromosomes 5q, 6q, and 10q in renal cell cancer. Cancer Res. 1991;51:5817-5820.
17. Tahara H, Smith AP, Gas RD, Cryns VL, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 1996;56:599-605.
18. Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 1991; 51:5449-5453.
19. Gaidano G, Hauptschein RS, Parsa NZ, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood. 1992;80:1781-1787.
20. Hayashi Y, Raimondi S, Look T, et al. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood. 1990;76:1626-1630.
21. Trubia M, Sessa L, Taramelli R. Mammalian Rh/T2/S-glycoprotein ribonuclease family genes: cloning of a human member located in a region of chromosome 6 (6q27) frequently deleted in human malignancies. Genomics. 1997;42:342-344.
22. Acquati F, Morelli C, Cinquetti R, et al. Cloning and characterization of a senescence inducing and Class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene. 2001;20:980-988.
23. Acquati F, Possati L, Ferrante L, et al. Tumor and metastasis suppression by the human RNASET2 gene. Int J Oncol. 2005;26:1159-1168.
24. Acquati F, Nucci C, Bianchi M, Taramelli R. Molecular cloning, tissue distribution, and chromosomal localization of the human homolog of the R2/Th/Stylar ribonuclease gene family. Methods Mol Biol. 2001;160:87-101.
25. Ausubel FM, Brent R, Kingston R, et al. Current Protocols in Molecular Biology. New York: John Wiley & Sons, Inc.; 1998.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
27. st edition. Freehold, NJ: Worthington Biochemical Corporation, 1972.
28. Lee I, Lee YH, Mikulski SM, Lee J, Covone K, Shogen K. Tumoricidal effects of onconase on various tumors. J Surg Oncol. 2000;73:164-171.
29. Ponoe ML. In vitro Matrigel angionesis assays. In: Murray JC, editor. Methods in Molecular Medicine. Volume 46: Angiogenesis Protocols. New York: Totowa Humana Press; 2001;205-209.
30. Hu GF, Strydom DJ, Fett JW, Riordan JF, Vallee BL. Actin is a binding protein for angiogenin. Proc Natl Acad Sci USA. 1993;90:1217-1221.
31. Bullard DE, Schold SC Jr, Bigner SH, Bigner DD. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol. 1981;40:410-427.
32. Cregg JM, Vedvick TS, Raschke WC. Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology. 1993;11:905-910.
33. Scorer CA, Buckholz RG, Clare JJ, Romanos MA. The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast Pichia pastoris. Gene. 1993;136:111-119.
34. Combeau C, Didry D, Carlier MF. Interaction between G-actin and myosin subfragment-1 probed by covalent crosslinking. J Biol Chem. 1992;267:14038- 14046.
35. Van Dijk J, Furch M, Derancourt J, et al. Differences in the ionic interaction of actin with the motor domains of non-muscle and muscle myosin II. Eur J Biochem. 1999;260:672-683.
36. Simm FC, Krietsch WK, Isenberg G. On the interaction of bovine seminal RNase with actin in vitro. Eur J Biochem. 1987;166:49-54.
37. Antignani A, Naddeo M, Cubellis MV, Russo A, D'Alessio G. Antitumor action of seminal ribonuclease, its dimeric structure, and its resistance to the cytosolic ribonuclease inhibitor. Biochemistry. 2001;40:3492-3496.
38. Matousek J. Ribonucleases and their antitumor activity. Comp Biochem Physiol C Toxicol Pharmacol. 2001;129:175-191.
39. Pardridge WM, Nowlin DM, Choi TB, Yang J, Calaycay J, Shively JE. Brain capillary 46,000 dalton protein is cytoplasmic actin and is localized to endothelial plasma membrane. J Cereb Blood Flow Metab. 1989;9:675-680.
40. Hu GF, Chang SI, Riordan JF, Vallee BL. An angiogenin-binding protein from endothelial cells. Proc Natl Acad Sci USA 1991;88:2227-2231.
41. Moroianu J, Fett JW, Riordan JF, Vallee BL. Actin is a surface component of calf pulmonary artery endothelial cells in culture. Proc Natl Acad Sci USA. 1993;90:3815-3819.
42. Liu Y, Emilion G, Mungall AJ, et al. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene. 2002;21:387-399.
43. Fujii T, Tachibana M, Dhar DK, et al. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res. 2003;23:2405-2411.
44. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57:81-86.
45. Xu G, Pan J, Martin C, Yeung SC. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:1769-1777.
46. Kuttner C, Beecken W-D, Berens A, Eckart A. Paclitaxel administration along with antiangiogenic therapy in HNSCC xenograft model. Int Poster J Dent Oral Med. 2001;3: poster 93.
47. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29:3-9.
48. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev. 2004;25:581-611.
49. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.